GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro ...

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

Key Points Interested in GSK PLC Sponsored ADR? Here are five stocks we like better. GSK is expanding oncology across lung, ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to buy "a potential best-in-class" T cell-engager aimed at treating multiple myeloma from China-based clinical-stage biotechnology company ...

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from China's Chimagen Biosciences for $750 ...

GSK PLC licensor Hansoh Pharmaceutical Group Co. Ltd., announced positive overall survival (OS) data from ARTEMIS-008, its ...

ARTEMIS-008 is a multicenter, randomized, open-label study in China, which enrolled 461 patients, with 230 receiving Ris-Rez 8.0 mg/kg every three weeks or topotecan 1.2 mg/m² on Days 1-5 of each ...

Previously, GSK had agreed with Chimagen to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune ...